Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NBTY Not "Trigger Happy," But Acquisitions Stay In Its Crosshairs

This article was originally published in The Tan Sheet

Executive Summary

NBTY hopes to remain a supplement industry giant in part by continuing to acquire other businesses, a strategy with an improving outlook as opportunities emerge during the global economic slump

You may also be interested in...



NBTY Prefers Strategic Over "Easy" Acquisitions, Looks To China

NBTY looks to continue making strategic rather than "easy" acquisitions and includes China in its target markets, President Harvey Kamil says

NBTY Prefers Strategic Over "Easy" Acquisitions, Looks To China

NBTY looks to continue making strategic rather than "easy" acquisitions and includes China in its target markets, President Harvey Kamil says

NBTY Prefers Strategic Over "Easy" Acquisitions, Looks To China

NBTY looks to continue making strategic rather than "easy" acquisitions and includes China in its target markets, President Harvey Kamil says

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel